Vaxcyte Inc. (PCVX) Financial Statements (2025 and earlier)

Company Profile

Business Address 825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS, CA 94070
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,452,697,0001,486,518,0001,080,227,0001,265,684,0001,287,064,000822,038,000
Cash and cash equivalents518,670,000611,512,000397,451,000545,134,000531,033,000380,451,000
Short-term investments934,027,000875,006,000682,776,000720,550,000756,031,000441,587,000
Receivables8,470,00016,009,0003,607,0005,324,000  
Prepaid expense9,177,0007,774,0006,159,00015,335,000  
Other current assets1,376,0002,092,0002,105,0001,299,000  
Other undisclosed current assets9,759,0004,679,0003,856,0007,792,00023,253,00018,636,000
Total current assets:1,481,479,0001,517,072,0001,095,954,0001,295,434,0001,310,317,000840,674,000
Noncurrent Assets
Operating lease, right-of-use asset26,779,00028,905,00030,997,00016,333,00018,006,00019,658,000
Property, plant and equipment125,973,00084,835,00079,626,00011,431,00016,420,00015,205,000
Long-term investments and receivables399,243,000413,247,000162,675,000168,564,000153,726,000127,815,000
Long-term investments399,243,000413,247,000162,675,000168,564,000153,726,000127,815,000
Restricted cash and investments1,103,0001,103,0001,103,0001,103,000871,000871,000
Other noncurrent assets52,690,00046,143,00037,562,0003,192,0003,479,0003,940,000
Total noncurrent assets:605,788,000574,233,000311,963,000200,623,000192,502,000167,489,000
TOTAL ASSETS:2,087,267,0002,091,305,0001,407,917,0001,496,057,0001,502,819,0001,008,163,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities32,619,00075,888,00074,402,00030,725,00035,446,00029,966,000
Accounts payable10,466,00021,717,00014,587,00015,704,00016,266,00011,615,000
Accrued liabilities22,153,00054,171,00059,815,00015,021,00019,180,00018,351,000
Other undisclosed current liabilities50,228,00011,216,00070,936,00054,833,00024,770,00022,781,000
Total current liabilities:82,847,00087,104,000145,338,00085,558,00060,216,00052,747,000
Noncurrent Liabilities
Liabilities, other than long-term debt18,288,00020,218,00022,111,0007,783,0009,227,00010,645,000
Other liabilities    2,0005,0007,000
Operating lease, liability18,288,00020,218,00022,111,0007,781,0009,222,00010,638,000
Total noncurrent liabilities:18,288,00020,218,00022,111,0007,783,0009,227,00010,645,000
Total liabilities:101,135,000107,322,000167,449,00093,341,00069,443,00063,392,000
Equity
Equity, attributable to parent1,986,132,0001,983,983,0001,240,468,0001,402,716,0001,433,376,000944,771,000
Common stock114,000112,00098,00098,00097,00084,000
Additional paid in capital3,132,318,0003,000,394,0002,164,583,0002,148,499,0002,086,727,0001,527,228,000
Accumulated other comprehensive income (loss)1,815,0002,889,000179,000(2,290,000)(2,521,000)47,000
Accumulated deficit(1,148,115,000)(1,019,412,000)(924,392,000)(743,591,000)(650,927,000)(582,588,000)
Total equity:1,986,132,0001,983,983,0001,240,468,0001,402,716,0001,433,376,000944,771,000
TOTAL LIABILITIES AND EQUITY:2,087,267,0002,091,305,0001,407,917,0001,496,057,0001,502,819,0001,008,163,000

Income Statement (P&L) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Operating expenses(152,981,000)(114,472,000)(196,676,000)(113,026,000)(87,147,000)(71,192,000)
Operating loss:(152,981,000)(114,472,000)(196,676,000)(113,026,000)(87,147,000)(71,192,000)
Nonoperating income
(Other Nonoperating income)
24,278,00019,452,00015,875,00020,362,00018,808,00010,730,000
Net loss attributable to parent:(128,703,000)(95,020,000)(180,801,000)(92,664,000)(68,339,000)(60,462,000)
Other undisclosed net income (loss) available to common stockholders, basic   (442,930,000)185,328,000  
Net income (loss) available to common stockholders, diluted:(128,703,000)(95,020,000)(623,731,000)92,664,000(68,339,000)(60,462,000)

Comprehensive Income (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(128,703,000)(95,020,000)(180,801,000)(92,664,000)(68,339,000)(60,462,000)
Comprehensive loss:(128,703,000)(95,020,000)(180,801,000)(92,664,000)(68,339,000)(60,462,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1,074,000)2,710,0002,469,000231,000(2,568,000)408,000
Comprehensive loss, net of tax, attributable to parent:(129,777,000)(92,310,000)(178,332,000)(92,433,000)(70,907,000)(60,054,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: